ReviewRSC advances2022
Nano-molecularly imprinted polymers (nanoMIPs) as a novel approach to targeted drug delivery in nanomedicine.
Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- Engineering molecularly imprinted polymers for receptor-specific cancer therapeutics.Nanoscale · 2026Review
- Crossing the Blood-Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- [Research progress in the application of molecular imprinting technology in catalysis].Se pu = Chinese journal of chromatography · 2026Article
- Review
- Advances in molecularly imprinted polymers for clinical biomarker detection (2021-2025).Mikrochimica acta · 2025Review
- Molecularly Imprinted Polymers Coupled with Cellulosic Paper-Based Analytical Devices for Biosensing Applications.Indian journal of microbiology · 2025Article
- Tuning the properties of peptide imprinted nanoparticles for protein immunoprecipitation using magnetic streptavidin beads.Mikrochimica acta · 2024Article
- Hazardous Materials from Threats to Safety: Molecularly Imprinted Polymers as Versatile Safeguarding Platforms.Polymers · 2024Review
- Preparation and application of a pseudo-templated multi-monomer aflatoxins imprinted polymer.Mikrochimica acta · 2024Article
- Nanotechnology innovations for increasing the productivity of poultry and the prospective of nanobiosensors.Veterinary medicine and science · 2023Review
- Article
- Review
- On-Demand, Reversible, Ultrasensitive Polymer Membrane Based on Molecular Imprinting Polymer.ACS nano · 2023Article
- Ruxolitinib-Loaded Imprinted Polymeric Drug Reservoir for the Local Management of Post-Surgical Residual Glioblastoma Cells.Polymers · 2023Article
- Electrochemical Sensor Based on a Composite of Reduced Graphene Oxide and Molecularly Imprinted Copolymer of Polyaniline-Poly(ACS omega · 2023Article
- In Vivo Applications of Molecularly Imprinted Polymers for Drug Delivery: A Pharmaceutical Perspective.International journal of molecular sciences · 2022Review
- Biodegradable Magnetic Molecularly Imprinted Anticancer Drug Carrier for the Targeted Delivery of Docetaxel.ACS omega · 2022Article
- Molecular imprinting as a tool for determining molecular markers: a lung cancer case.RSC advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted polymers - MIPs - denote synthetic polymeric structures that selectively recognize the molecule of interest against which MIPs are templated. A number of works have demonstrated that MIPs can exceed the affinity and selectivity of natural antibodies, yet operating by the same principle of "lock and key". In contrast to antibodies, which have certain limitations related to the minimal size of the antigen, nanoMIPs can be fabricated against almost any target molecule irrespective of its size and low immunogenicity. Furthermore, the cost of MIP production is much lower compared to the cost of antibody production. Excitingly, MIPs can be used as nanocontainers for specific delivery of therapeutics both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.